Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (271-280 of 336) with videos related to

Pageof 34
Sort By:
Journal of the National Cancer Institute|December 26, 2022
Cognitive change in breast cancer patients up to 2 years after diagnosisMarie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Gynecologic Oncology|July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer databaseAlexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
Nature Communications|January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trialIsabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JCO Precision Oncology|January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialFélix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
Pageof 34

Showing results (271-280 of 336) with videos related to

Sort By:
Pageof 34
Journal of the National Cancer Institute|December 26, 2022
Cognitive change in breast cancer patients up to 2 years after diagnosisMarie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, et al.
Acta Oncologica (Stockholm, Sweden)|February 21, 2013
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysisBenoit Beuselinck, Alexandra Karadimou, Diether Lambrechts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2014
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumorsEric Angevin, Josep Tabernero, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2023
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
Gynecologic Oncology|July 23, 2021
Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer databaseAlexandre De Nonneville, Christophe Zemmour, Sophie Frank, et al.
Nature Communications|January 6, 2026
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trialIsabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, Ryotaro Ohkuma, et al.
JCO Precision Oncology|January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialFélix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2025
GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 ConsortiumNicole Concin, Ioana Braicu, Pierre Combe, et al.
Pageof 34